Get to know our clinical trials

Phase 1 dose-finding clinical trial to assess the safety and preliminary efficacy of CRISPR-Cas9 genome-edited anti-CD19 allogeneic T cells in adult subjects with refractory autoimmune diseases.

Imagen Dr. Enrique Ornilla Laraundogoitia, Departamento de Reumatología.
Dr. Enrique Ornilla Curriculum
Specialist Rheumatology Service
Navarre headquarters
Status
In recruitment
headquarters
Pamplona
Early phase

Technical Summary

  • PHASE 1 DOSE-FINDING STUDY TO DETERMINE THE SAFETY AND PRELIMINARY EFFICACY OF CRISPR-CAS9 GENOME-EDITED ANTI-CD19 ALLOGENEIC T CELLS (CTX112) IN ADULT SUBJECTS WITH TREATMENT-RESISTANT AUTOIMMUNE DISEASES.
  • Code EudraCT: 2024-518528-54
  • Protocol number: CRSP-AID-500
  • Promoter: CRISPR Therapeutics AG
  • Molecule/Drug: CTX112
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION